Your browser doesn't support javascript.
Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial.
Verweij, Lynn; Ector, Geneviève I C G; Smit, Yolba; van Vlijmen, Bas; van der Reijden, Bert A; Hermens, Rosella P M G; Blijlevens, Nicole M A.
  • Verweij L; Department of Hematology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands. lynn.verweij@radboudumc.nl.
  • Ector GICG; Department of Hematology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands.
  • Smit Y; Department of Hematology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands.
  • van Vlijmen B; Department of Pharmacy, Radboud University Medical Center, Nijmegen, Netherlands.
  • van der Reijden BA; Department of Laboratory Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands.
  • Hermens RPMG; Department of IQ Healthcare, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands.
  • Blijlevens NMA; Department of Hematology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands.
BMC Health Serv Res ; 23(1): 228, 2023 Mar 08.
Article in English | MEDLINE | ID: covidwho-2285483
ABSTRACT

BACKGROUND:

Two most important factors determining treatment success in chronic myeloid leukemia (CML) are adequate medication compliance and molecular monitoring albeit still being suboptimal. The CMyLife platform is an eHealth innovation, co-created with and for CML patients, aiming to improve their care, leading to an increased quality of life and the opportunity of hospital-free care.

OBJECTIVE:

To explore the effectiveness of CMyLife in terms of information provision, patient empowerment, medication compliance, molecular monitoring, and quality of life.

METHODS:

Effectiveness of CMyLife was explored using a patient-preference trial. Upon completion of the baseline questionnaire, participants actively used (intervention group) or did not actively use (questionnaire group) the CMyLife platform for at least 6 months, after which they completed the post-intervention questionnaire. Scores between the intervention group and the questionnaire group were compared with regard to the within-subject change between baseline and post-measurement using Generalized Estimating Equation models.

RESULTS:

At baseline, 33 patients were enrolled in the questionnaire group and 75 in the intervention group. Online health information knowledge improved significantly when actively using CMyLife and patients felt more empowered. No significant improvements were found regarding medication compliance and molecular monitoring, which were already outstanding. Self-reported effectiveness showed that patients experienced that using CMyLife improved their medication compliance and helped them to oversee their molecular monitoring. Patients using CMyLife reported more symptoms but were better able to manage these.

CONCLUSIONS:

Since hospital-free care has shown to be feasible in time of the COVID-19 pandemic, eHealth-based innovations such as CMyLife could be a solution to maintain the quality of care and make current oncological health care services more sustainable. TRIAL REGISTRATION ClinicalTrials.gov NCT04595955 , 22/10/2020.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: BMC Health Serv Res Journal subject: Health Services Research Year: 2023 Document Type: Article Affiliation country: S12913-023-09153-9

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: BMC Health Serv Res Journal subject: Health Services Research Year: 2023 Document Type: Article Affiliation country: S12913-023-09153-9